The patient-derived xenograft model market size is expected to grow from US$ 378.46 million in 2022 to US$ 975.31 million by 2030; it is projected to register a CAGR of 12.6% during 2022-2030.
The patient-derived xenograft (PDX) model refers to laboratory models that are created by implanting patient tumor tissues directly into immunodeficient mice. These models play a crucial role in tumor biology studies, drug efficacy evaluation studies, and predicting patients' responses to various treatments. These models are created by implanting patient-derived tumor tissues from cancer patients into immunodeficient mice, allowing human tumors to grow and study in a controlled laboratory setting. They are particularly useful in the field of precision oncology, where treatments are tailored to individual patients based on their unique genetic profiles. The patient-derived xenograft model market growth is attributed to growing awareness of the advantages of humanized PDX models and the rising demand for personalized medicine. However, significant operational costs associated with the PDX model hinder the patient-derived xenograft model market growth.
Researchers can construct more accurate and sophisticated models that closely resemble human disease conditions by using the CRISPR technology that enables DNA modification in PDX models in a fast, precise, and exact manner. With the help of CRISPR-mediated modifications, it is possible to replicate patient-specific genetic changes observed in various diseases, including cancer, by adding specific mutations, deletions, or insertions into PDX models. This feature enhances the PDX models authenticity and makes it easier to investigate the genetic causes of disease and its mechanisms. Through the use of CRISPR-edited PDX models, researchers can gain a deeper understanding of the role of specific genes and pathways in tumor growth, progression, and response to treatment, thereby providing insightful discoveries on tailored therapeutic approaches. Thus, the emergence of CRISPR in biomedical research offers a significant opportunity for the expansion of the patient-derived xenograft model market in the coming years.
The expanding partnership in the industry also provides a potential opportunity for the growth of the patient-derived xenograft model market during the forecast period. For instance, in July 2022, GemPharmatech entered into a strategic license agreement with Charles River Laboratories to exclusively distribute its next-generation NOD CRISPR Prkdc Il2r gamma (NCG) mouse lines in North America. The agreement aims to speed up the development of novel therapeutics for a variety of unmet medical needs, particularly in immuno-oncology. Under the terms of the agreement, GemPharmatech gave Charles River access to its exclusive range of NCG derivative products for use in breeding and distribution in specific markets. One of the most complete portfolios of immunodeficient research models is the NCG derivative product line. Preclinical cancer immunotherapy research can benefit from the use of human peripheral blood mononuclear cells, human hematopoietic stem cells, PDX, and immune system reconstitution utilizing NCG-based mice. In addition, Charles River is the lone distributor of NCG mice in North America, and the collaboration increases the range of NCG models available to Charles River. Therefore, the patient-derived xenograft model market is expected to rise in the future.
Application-Based Insights
Based on application, the patient-derived xenograft model market is categorized into preclinical drug development, biomarker analysis, translational research, and biobanking. In 2022, the preclinical drug development segment held a significant patient-derived xenograft model market share. The segment is estimated to record the highest CAGR during 2022-2030. The drug development process is usually divided into three main steps: discovery, preclinical development, and clinical trials. Preclinical development involves activities that combine laboratory drug discovery with the initiation of human clinical trials. To initiate the preclinical drug development phase, animal testing plays a crucial role in checking the efficacy, potency, and ADRs. Mice models are the most widely used for drug testing among all animals. For instance, at Pfizer, 99% of the animals are rats and mice.
End User-Based Insights
The patient-derived xenograft model market is segmented based on end users into pharmaceutical and biotechnology companies, contract research organizations, and academic and government research institutions. The academic and government research institutions segment held the major patient-derived xenograft model market share in 2022 and is expected to register the highest CAGR during 2022-2030.
Breast Cancer Organization, Centers for Disease Control and Prevention, GLOBOCAN, and the World Health Organization are among the primary and secondary sources referred to while preparing the patient-derived xenograft model market report.
- Home
- Life Sciences
- Patient-Derived Xenograft Model Market Size and F..
patient-derived xenograft model Market
Patient-Derived Xenograft Model Market Size and Forecasts (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Model Type (Mice Models and Rats Models), Tumor Type (Gastrointestinal Tumor Models, Gynecological Tumor Models, Respiratory Tumor Models, and Other Tumor Models), Application (Preclinical Drug Development, Biomarker Analysis, Translational Research, and Biobanking), End User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations, and Academic and Government Research Institutions), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
- Code: TIP00069641
- The Insight Partners
- Feb-2024
- Life Sciences
- 150 Pages
- Published
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 Market Definition, Assumptions and Limitations
1.3 Market Segmentation
2. Executive Summary
2.1 Key Insights
2.2 Market Attractiveness Analysis
3. Research Methodology
4. Patient-Derived Xenograft Models Market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
4.3.1 List of Vendors in the Value Chain
5. Patient-Derived Xenograft Models Market - Key Market Dynamics
5.1 Key Market Drivers
5.2 Key Market Restraints
5.3 Key Market Opportunities
5.4 Future Trends
5.5 Impact Analysis of Drivers and Restraints
6. Patient-Derived Xenograft Models Market - Global Market Analysis
6.1 Patient-Derived Xenograft Models - Global Market Overview
6.2 Patient-Derived Xenograft Models - Global Market and Forecast to 2030
7. Patient-Derived Xenograft Models Market - Revenue Analysis (USD Million) - By Type, 2020-2030
7.1 Overview
7.2 Mice Model
7.3 Rats Model
8. Patient-Derived Xenograft Models Market - Revenue Analysis (USD Million) - By Tumor Type, 2020-2030
8.1 Overview
8.2 Gastrointestinal Tumor Model
8.3 Gynecological Tumor Model
8.4 Respiratory Tumor Model
8.5 Other Tumor Model
9. Patient-Derived Xenograft Models Market - Revenue Analysis (USD Million) - By Application, 2020-2030
9.1 Overview
9.2 Preclinical Drug Development
9.3 Biomarker Analysis
9.4 Translational Research
9.5 Biobanking
10. Patient-Derived Xenograft Models Market - Revenue Analysis (USD Million) - By End Users, 2020-2030
10.1 Overview
10.2 Pharmaceutical and Biotechnology Companies
10.3 Academic and Government Research Institutions
10.4 Contract Research Organizations
11. Patient-Derived Xenograft Models Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis
11.1 North America
11.1.1 North America Patient-Derived Xenograft Models Market Overview
11.1.2 North America Patient-Derived Xenograft Models Market Revenue and Forecasts to 2030
11.1.3 North America Patient-Derived Xenograft Models Market Revenue and Forecasts and Analysis - By Type
11.1.4 North America Patient-Derived Xenograft Models Market Revenue and Forecasts and Analysis - By Tumor Type
11.1.5 North America Patient-Derived Xenograft Models Market Revenue and Forecasts and Analysis - By Application
11.1.6 North America Patient-Derived Xenograft Models Market Revenue and Forecasts and Analysis - By End Users
11.1.7 North America Patient-Derived Xenograft Models Market Revenue and Forecasts and Analysis - By Countries
11.1.7.1 United States Patient-Derived Xenograft Models Market
11.1.7.1.1 United States Patient-Derived Xenograft Models Market, by Type
11.1.7.1.2 United States Patient-Derived Xenograft Models Market, by Tumor Type
11.1.7.1.3 United States Patient-Derived Xenograft Models Market, by Application
11.1.7.1.4 United States Patient-Derived Xenograft Models Market, by End Users
11.1.7.2 Canada Patient-Derived Xenograft Models Market
11.1.7.2.1 Canada Patient-Derived Xenograft Models Market, by Type
11.1.7.2.2 Canada Patient-Derived Xenograft Models Market, by Tumor Type
11.1.7.2.3 Canada Patient-Derived Xenograft Models Market, by Application
11.1.7.2.4 Canada Patient-Derived Xenograft Models Market, by End Users
11.1.7.3 Mexico Patient-Derived Xenograft Models Market
11.1.7.3.1 Mexico Patient-Derived Xenograft Models Market, by Type
11.1.7.3.2 Mexico Patient-Derived Xenograft Models Market, by Tumor Type
11.1.7.3.3 Mexico Patient-Derived Xenograft Models Market, by Application
11.1.7.3.4 Mexico Patient-Derived Xenograft Models Market, by End Users
Note - Similar analysis would be provided for below mentioned regions/countries
11.2 Europe
11.2.1 Germany
11.2.2 France
11.2.3 Italy
11.2.4 Spain
11.2.5 United Kingdom
11.2.6 Rest of Europe
11.3 Asia-Pacific
11.3.1 Australia
11.3.2 China
11.3.3 India
11.3.4 Japan
11.3.5 South Korea
11.3.6 Rest of Asia-Pacific
11.4 Middle East and Africa
11.4.1 South Africa
11.4.2 Saudi Arabia
11.4.3 U.A.E
11.4.4 Rest of Middle East and Africa
11.5 South and Central America
11.5.1 Brazil
11.5.2 Argentina
11.5.3 Rest of South and Central America
12. Industry Landscape
12.1 Mergers and Acquisitions
12.2 Agreements, Collaborations, Joint Ventures
12.3 New Product Launches
12.4 Expansions and Other Strategic Developments
13. Competitive Landscape
13.1 Heat Map Analysis by Key Players
13.2 Company Positioning and Concentration
14. Patient-Derived Xenograft Models Market - Key Company Profiles
14.1 Champions Oncology, Inc.
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
Note - Similar information would be provided for below list of companies
14.2 Charles River Laboratories, Inc.
14.3 Crown Bioscience, Inc.
14.4 EPO Berlin-Buch GmbH
14.5 Hera BioLabs
14.6 Horizon Discovery Group plc
14.7 Oncodesign
14.8 Pharmatest Services Ltd
14.9 Xentech SAS
14.10 JSR Corporation
15. Appendix
15.1 Glossary
15.2 About
15.3 Market Intelligence Cloud
LIST OF TABLES
LIST OF FIGURES
The List of Companies - Patient-Derived Xenograft Model Market
- Champions Oncology Inc.
- Charles River Laboratories Inc.
- Crown Bioscience Inc.
- EPO Berlin-Buch GmbH
- Hera BioLabs
- Horizon Discovery Group plc
- Oncodesign
- Pharmatest Services Ltd
- Xentech SAS
- JSR Corporation.